RLAY vs TEM
RLAY and TEM side by side — valuation & fundamentals (public data).
Key statistics
| Metric | RLAYRelay Therapeutics, Inc. | TEMTempus AI, Inc. |
|---|---|---|
| Market cap | $4.02B | $12.96M |
| P/B | — | 0.03 |
| P/S | 261.6x | 0.0x |
| Revenue | — | $1.43B(TTM) |
| Revenue growth (YoY) | 53.4% | 83.4% |
| Net income | — | -$254.40M(TTM) |
| Earnings growth (YoY) | 18.1% | 65.3% |
| EPS, diluted | — | $-1.44(TTM) |
| EBIT margin | -1971.6% | -19.9% |
| ROE | -31.1% | -55.1% |
| 1y total return | +149.6% | -16.3% |
Figures from SEC filings · for reference only · not investment advice
Crecimiento de $10,000: RLAY frente a TEM
| Métrica | RLAY | TEM |
|---|---|---|
| Valor final | $25.1K | $17.9K |
| Retorno total | +151.0% | +79.4% |
| CAGR | +47.3% | +27.9% |
| Volatilidad | 77.5% | 97.0% |
| Sharpe | 0.81 | 0.68 |
| Sortino | 1.39 | 1.09 |
| Caída máxima | -79.0% | -59.8% |
Basado en 597 días de negociación comunes, 2024-06-14 → 2026-10-30 · tasa libre de riesgo 4.16% (bono corto del Tesoro actual, mantenido constante)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)